Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2098

1.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
5.

Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).

Zareba W, Piotrowicz K, McNitt S, Moss AJ; MADIT II Investigators..

Am J Cardiol. 2005 Jun 15;95(12):1487-91.

PMID:
15950580
6.

Amiodarone: clinical trials.

Naccarelli GV, Wolbrette DL, Patel HM, Luck JC.

Curr Opin Cardiol. 2000 Jan;15(1):64-72. Review.

PMID:
10666663
8.

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.

Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.

Am J Cardiol. 1997 Sep 11;80(5B):3F-9F.

PMID:
9291444
9.

Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.

Hilleman DE, Bauman AL.

Pharmacotherapy. 2001 May;21(5):556-75. Review.

PMID:
11349745
10.

Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.

Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.

Kardiol Pol. 2012;70(11):1099-110.

11.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

12.

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):440-8.

PMID:
12228780
13.
15.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2005;5(14):1-74.

17.

Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".

Böcker D, Breithardt G.

Am J Cardiol. 1999 Mar 11;83(5B):83D-87D. Review.

PMID:
10089846
19.

The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.

Lau EW, Griffith MJ, Pathmanathan RK, Ng GA, Clune MM, Cooper J, Marshall HJ, Forsey PR, Stafford PJ, Gray RG, Skehan JD, Garratt CJ.

Europace. 2004 Jul;6(4):257-66.

PMID:
15172648
20.

Amiodarone: what have we learned from clinical trials?

Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC.

Clin Cardiol. 2000 Feb;23(2):73-82. Review.

Supplemental Content

Support Center